Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genus plc ( (GB:GNS) ) has issued an announcement.
Genus plc has secured regulatory approval in Canada for the use of its gene-edited PRRS Resistant Pig (PRP), marking a key milestone toward commercialising the technology in North America after years of collaboration with Canadian authorities. The company views this clearance as a significant step but notes that further approvals in major North American export markets, particularly Mexico and Japan, as well as in other jurisdictions including China, will be critical to full rollout, especially given the heavy economic and animal health burden of PRRS, which costs U.S. producers an estimated $1.2 billion annually and has been linked to sharply higher antibiotic use.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £2954.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score is driven by strong corporate events and solid financial performance. However, technical indicators suggest caution due to potential overbought conditions, and the high P/E ratio indicates possible overvaluation.
To see Spark’s full report on GB:GNS stock, click here.
More about Genus plc
Genus plc is a world-leading animal genetics company that applies biotechnology to improve livestock breeding, supplying value-added genetic products such as semen, embryos and breeding animals for the dairy, beef and pork sectors in more than 75 countries under its ABS and PIC brands. The group’s competitive advantage lies in its proprietary breeding lines, genetic improvement technologies and global supply and service network, with operations across six continents and research laboratories in Madison, Wisconsin, and it is developing its PRRS Resistant Pig (PRP) as a major gene-editing innovation for the porcine industry.
Average Trading Volume: 151,343
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.84B
For a thorough assessment of GNS stock, go to TipRanks’ Stock Analysis page.